Latest Merck Stories
NEW YORK and ANN ARBOR, Mich., March 25, 2015 /PRNewswire/ -- Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced
Merkerson Visits Memphis, Tennessee on March 20 With America's Diabetes Challenge: Get to Your Goals Program KENILWORTH, N.J., March 20, 2015 /PRNewswire/ -- Merck (NYSE: MRK), known
Submission of Application in Japan Marks an Important Milestone in Strategic Partnership With Amgen Astellas BioPharma THOUSAND OAKS, Calif., March 20, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN)
Data From PCSK9 Inhibitor Study Support Regulatory Filing in Japan THOUSAND OAKS, Calif., March 14, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase
-- Collaboration strengthens company's position as a leader in precision medicine in oncology ROCKLAND, Mass., March 10, 2015 /PRNewswire/ -- EMD Serono today announced that the biopharmaceutical
- Personalized immunotherapy Tcelna (imilecleucel-T), an investigational compound currently in a Phase IIb clinical study in patients with secondary progressive multiple sclerosis (SPMS), an area of
CAMBRIDGE, England, February 11, 2015 /PRNewswire/ -- - New technology makes bendable, light, thin and unbreakable liquid crystal displays (LCDs)
- EMD Millipore services include design and development of cost-effective process to deliver high yield and productivity DARMSTADT, Germany, Feb.
- New AFS® 40E / 80E / 120E and 150E systems fulfill pure water needs for one or several high-throughput clinical analyzers DARMSTADT, Germany, Jan.